Seliciclib in malignancies
- 23 October 2009
- journal article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 18 (12) , 1957-1965
Abstract
(2009). Seliciclib in malignancies. Expert Opinion on Investigational Drugs: Vol. 18, No. 12, pp. 1957-1965. doi: 10.1517/13543780903418445Keywords
This publication has 61 references indexed in Scilit:
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatmentJournal of Cellular Biochemistry, 2009
- Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinasesExpert Opinion on Drug Discovery, 2007
- A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 daysBritish Journal of Cancer, 2006
- (R)-Roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosisExperimental Cell Research, 2006
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase PathwayCancer Research, 2004
- Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical TrialsAccounts of Chemical Research, 2003
- Cancer Cell CyclesScience, 1996
- Aberrations of p16Ink4 and retinoblastoma tumour‐suppressor genes occur in distinct sub‐sets of human cancer cell linesInternational Journal of Cancer, 1995